Feature | May 23, 2014

New Data Show Defibrillators Programmed to Wait Longer to Deliver Therapy Safer for Secondary Prevention ICD Patients

May 23, 2014 — Medtronic announced the results from the first prospective randomized clinical trial to show that Medtronic implantable cardioverter-defibrillators (ICDs) can safely extend detection times before triggering therapy in secondary prevention patients. The results of the PainFree SST sub-study, unveiled as a late-breaking presentation at the Heart Rhythm Society's (HRS) 35th annual scientific sessions, demonstrate that physicians can choose to program ICDs with delayed detection interval settings without compromising safety for high-risk patients.

Previous studies of prolonged interval detection have focused on primary prevention patients, who have not experienced an episode of sudden cardiac arrest but are at risk. Secondary prevention patients are at higher risk for a deadly irregular heart rhythm, having already experienced an episode of sudden cardiac arrest.

“The results of this study are important for secondary prevention patients, who often are treated with more aggressive ICD programming to address arrhythmic events as quickly as possible," said Laurence D. Sterns, M.D., cardiologist at Royal Jubilee Hospital in Victoria, British Columbia, Canada. "Previous studies have demonstrated that devices programmed to wait longer to deliver therapy do not increase the risk of fainting episodes among primary prevention patients, and now we know the same strategy can be safely used in more patients, even patients at increased risk based on their disease progression."

Patients in the PainFree SST trial received Protecta ICDs with SmartShock technology, an exclusive shock reduction algorithm that enables the devices to better differentiate between dangerous and harmless heart rhythms. Secondary prevention participants were randomized into two groups: an extended interval detection group (30/40 intervals) and a standard interval detection group (18/24 intervals).

The study found that longer detection intervals did not significantly increase the risk of fainting episodes among secondary prevention patients after one-year of follow-up, establishing the safety of this programming strategy among higher-risk patients. The number of patients with syncope events within 24 hours of a device-detected arrhythmic event was similar between groups. Patients programmed to receive standard interval detection were 98 percent free of arrhythmic fainting episodes, compared to 96.9 percent of patients programmed to receive prolonged interval detection.

The study results also revealed that the portion of patients receiving inappropriate shocks, or unnecessary therapy delivered in response to benign arrhythmias or electrical noise sensed by the device, was low and not different between groups. After one year, only 1 percent of patients in the standard detection group and 1.3 percent of patients in the extended interval detection received inappropriate shocks.

“ICDs are extremely effective in treating dangerously fast ventricular arrhythmias that can lead to sudden cardiac arrest. Through scientific research and technological advances, Medtronic has successfully reduced the rate of inappropriate shock for ICD patients, helping to clear the way for more patients to benefit from this life-saving technology," said Marshall Stanton, M.D., vice president and general manager, Implantable Defibrillator Business, Cardiac Rhythm Disease Management at Medtronic.

For more information: www.medtronic.com

Related Content

Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init